These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 22771813)

  • 1. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
    Mastinu A; Pira M; Pani L; Pinna GA; Lazzari P
    Behav Brain Res; 2012 Oct; 234(2):192-204. PubMed ID: 22771813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NESS06SM reduces body weight with an improved profile relative to SR141716A.
    Mastinu A; Pira M; Pinna GA; Pisu C; Casu MA; Reali R; Marcello S; Murineddu G; Lazzari P
    Pharmacol Res; 2013 Aug; 74():94-108. PubMed ID: 23756200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice.
    Lazzari P; Sanna A; Mastinu A; Cabasino S; Manca I; Pani L
    Behav Brain Res; 2011 Mar; 217(2):432-8. PubMed ID: 21074566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
    Hsiao WC; Shia KS; Wang YT; Yeh YN; Chang CP; Lin Y; Chen PH; Wu CH; Chao YS; Hung MS
    Diabetes Obes Metab; 2015 May; 17(5):495-504. PubMed ID: 25656402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
    Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG
    Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Cannabinoid Receptor 1 Can Influence the Lipid Metabolism in Mice with Diet-Induced Obesity.
    Wei LW; Yuan ZQ; Zhao MD; Gu CW; Han JH; Fu L
    Biochemistry (Mosc); 2018 Oct; 83(10):1279-1287. PubMed ID: 30472964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
    Després JP; Ross R; Boka G; Alméras N; Lemieux I;
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
    Chen W; Tang H; Liu H; Long L; Gong Z; Zheng J; Chi M; Xie Y; Zheng Z; Li S; Wang L
    Eur J Pharmacol; 2010 Jul; 637(1-3):178-85. PubMed ID: 20380831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile.
    Poirier B; Bidouard JP; Cadrouvele C; Marniquet X; Staels B; O'Connor SE; Janiak P; Herbert JM
    Diabetes Obes Metab; 2005 Jan; 7(1):65-72. PubMed ID: 15642077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
    Wang Q; Perrard XD; Perrard JL; Mansoori A; Smith CW; Ballantyne CM; Wu H
    Obesity (Silver Spring); 2011 Mar; 19(3):505-13. PubMed ID: 20885384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.
    Ravinet Trillou C; Arnone M; Delgorge C; Gonalons N; Keane P; Maffrand JP; Soubrie P
    Am J Physiol Regul Integr Comp Physiol; 2003 Feb; 284(2):R345-53. PubMed ID: 12399252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
    Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of inflammation-induced impairment of glucose uptake in adipocytes by direct effect of CB1 antagonism on adipose tissue macrophages.
    Miranville A; Herling AW; Biemer-Daub G; Voss MD
    Obesity (Silver Spring); 2010 Dec; 18(12):2247-54. PubMed ID: 20379144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
    Jbilo O; Ravinet-Trillou C; Arnone M; Buisson I; Bribes E; Péleraux A; Pénarier G; Soubrié P; Le Fur G; Galiègue S; Casellas P
    FASEB J; 2005 Sep; 19(11):1567-9. PubMed ID: 16009704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice.
    Verty AN; Lockie SH; Stefanidis A; Oldfield BJ
    Int J Obes (Lond); 2013 Feb; 37(2):279-87. PubMed ID: 22473329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.
    Ravinet Trillou C; Delgorge C; Menet C; Arnone M; Soubrié P
    Int J Obes Relat Metab Disord; 2004 Apr; 28(4):640-8. PubMed ID: 14770190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.
    Chen W; Chen Z; Xue N; Zheng Z; Li S; Wang L
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Aug; 386(8):721-32. PubMed ID: 23620336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.
    Jourdan T; Djaouti L; Demizieux L; Gresti J; Vergès B; Degrace P
    Diabetes; 2010 Apr; 59(4):926-34. PubMed ID: 20110567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of microRNA in CB1 antagonist-mediated regulation of adipose tissue macrophage polarization and chemotaxis during diet-induced obesity.
    Mehrpouya-Bahrami P; Miranda K; Singh NP; Zumbrun EE; Nagarkatti M; Nagarkatti PS
    J Biol Chem; 2019 May; 294(19):7669-7681. PubMed ID: 30910812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.